Betta Pharmaceuticals applies for H-share listing on Hong Kong Stock Exchange

Betta Pharmaceuticals Co., Ltd. submitted an application to The Stock Exchange of Hong Kong Limited on September 29, 2025, for the issuance and listing of its offshore shares (H-shares) on the Main Board. The draft application materials were simultaneously published on the Hong Kong Stock Exchange's website. These materials, compiled according to regulatory requirements, may be updated and revised.

This application for the issuance and listing of H-shares is exclusively for qualified offshore investors and eligible domestic investors permitted to invest in offshore securities under relevant Chinese laws and regulations. The company will not publish these materials on mainland Chinese stock exchange websites or media outlets.

However, to keep domestic investors informed, the company has provided links to the application materials on the Hong Kong Stock Exchange website. The successful issuance and listing are subject to approvals from various regulatory bodies, including the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange, and are dependent on market conditions and other factors.